Posted by Michael Wonder on 03 Apr 2021
Taltz (ixekizumab) approved by Health Canada for the treatment of paediatric patients (six to less than 18 years of age) with moderate to severe plaque psoriasis
2 April 2021 - On 29 March 2021, Health Canada issued a Notice of Compliance for Taltz (ixekizumab) injection, 80 mg/mL, for the treatment of paediatric patients from six to less than 18 years of age with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The efficacy, safety, and tolerability of Taltz in patients ages six to less than 18 years of age was demonstrated in a randomised, double-blind, placebo-controlled Phase 3 study that included 171 patients with moderate- to severe plaque psoriasis.
